Designing Smaller CCK Peptides That Trigger Satiety for Obesity Treatment
New hybrid CCK-A receptor agonist peptides combining features of hexa- and tetrapeptide classes showed potent satiety-inducing activity, advancing the design of peptide-based obesity treatments.
Quick Facts
What This Study Found
Hybrid CCK-A agonist peptides combining structural features of hexapeptide and tetrapeptide classes showed potent receptor binding and selectivity, advancing design of satiety-inducing peptide drugs for obesity.
Key Numbers
How They Did This
In-vitro study designing and testing new CCK peptide analogs for CCK-A receptor binding affinity, selectivity over CCK-B, and functional activity.
Why This Research Matters
Obesity is a global health crisis. CCK-based drugs that trigger natural satiety could help people eat less without the side effects of stimulant-based appetite suppressants.
The Bigger Picture
The body has built-in satiety signals. Rather than suppressing appetite artificially, drugs that enhance natural satiety peptide signaling could provide safer, more effective obesity treatment.
What This Study Doesn't Tell Us
In-vitro binding and selectivity data only. In-vivo satiety effects not demonstrated for the new hybrids. Peptide stability and oral bioavailability are ongoing challenges.
Questions This Raises
- ?Can these hybrids be made orally bioavailable?
- ?Do they produce sustained satiety in animal feeding studies?
- ?How do they compare to GLP-1-based obesity drugs?
Trust & Context
- Key Stat:
- Potent + selective Hybrid CCK peptides achieved strong CCK-A binding (satiety) with selectivity over CCK-B (avoids unwanted anxiety effects)
- Evidence Grade:
- Preliminary in-vitro evidence with clear receptor pharmacology but no in-vivo efficacy data.
- Study Age:
- Published in 2000. CCK-based obesity approaches have been explored further, though GLP-1 agonists have dominated the obesity drug landscape.
- Original Title:
- CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
- Published In:
- Journal of medicinal chemistry, 43(12), 2350-5 (2000)
- Authors:
- Pierson, M E, Comstock, J M, Simmons, R D, Julien, R, Kaiser, F, Rosamond, J D
- Database ID:
- RPEP-00612
Evidence Hierarchy
Frequently Asked Questions
What is CCK?
Cholecystokinin is a gut hormone released after eating that tells your brain you're full. Drugs that mimic CCK could help people feel satisfied sooner and eat less — a natural approach to weight management.
How does this compare to drugs like Ozempic?
Ozempic works through the GLP-1 system, a different satiety pathway. CCK-based drugs would target another satiety signal. In theory, combining both could produce even stronger satiety effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00612APA
Pierson, M E; Comstock, J M; Simmons, R D; Julien, R; Kaiser, F; Rosamond, J D. (2000). CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.. Journal of medicinal chemistry, 43(12), 2350-5.
MLA
Pierson, M E, et al. "CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.." Journal of medicinal chemistry, 2000.
RethinkPeptides
RethinkPeptides Research Database. "CCK peptides with combined features of hexa- and tetrapeptid..." RPEP-00612. Retrieved from https://rethinkpeptides.com/research/pierson-2000-cck-peptides-with-combined
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.